TLR4 and colorectal carcinoma: PVIGs in combination with other colostral components (e.g., lipoprotein-binding proteins, vitamins, lactoferrin) are thus thought to have the potential to correct perturbations of the immune response (e.g., TLR4/CD14 signaling pathway) known to occur in cancer, particularly in CRC (2, 21–25).